Early macrophage and cytokine response during the growth of immunogenic and non-immunogenic murine tumors.
Very little data exist on the mechanisms of innate immunity during the first days after syngeneic tumor inoculation. Nonspecific macrophage reaction precedes the development of specific immune response and is important for further tumor growth and stroma formation. We investigated two lymphoma cell lines of the same origin, differing in immunogenicity: non-immunogenic parental strain P388 and its highly immunogenic subline P388/adria. Early systemic inflammatory response resulted in the enhancement of nitric oxide (NO) and superoxide production by peritoneal macrophages which was at a maximum on the first day after s.c. tumor inoculation and was observed in mice bearing either of these tumors independently of immunogenicity. It was followed by a transient elevation of the serum levels of pro-inflammatory cytokines: TNF-alpha IL-6. In order to evaluate the role of inflammatory response, vaccinations with lethally irradiated lymphoma cells were performed. After two weekly injections, the mice were challenged s.c. with live tumor cells of the same subline. Effective vaccination with P388/adria lymphoma cells induced retardation of tumor growth in parallel with down-regulation of peritoneal macrophage activity and abrogation of serum cytokine release. Non-effective immunization with P388 cells influenced neither tumor growth nor macrophage functions and cytokine level. Thus, a positive correlation was found between down-regulation of the inflammatory response and inhibition of tumor growth. We suppose that, in efficiently immunized mice, special mechanisms exist which are responsible for down-regulation of the inflammatory reaction. Macrophage products may facilitate tumor cell survival by preventing apoptosis or participate in the activation of tumor neoangiogenesis. Suppression of these activities may serve as an important tool for the inhibition of tumor growth at the early stages of malignant transformation.
Kisseleva
E
E
Institute for Experimental Medicine, St Petersburg, Russia.
Becker
M
M
Lemm
M
M
Fichtner
I
I
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology*; D005260:Female; D007941:Leukemia P388 / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000276:immunology*; D051379:Mice; D008811:Mice, Inbred DBA
D019496:Cancer Vaccines; D016207:Cytokines